Evidence map›Paper›PMID 26292645›Full record

Trial reportInternational ophthalmology2016

Systemic oxygen therapy versus oral enalapril for treatment of diabetic macular ischemia: a randomized controlled trial.

Farideh Sharifipour, Mohammadreza Razzaghi, Alireza Ramezani, Mohsen Azarmina, Mehdi Yaseri, Roham Soheilian, Masoud Soheilian

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Farideh SharifipourDepartment of Ophthalmology and Ophthalmic Research Center, Labbafinejad Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St., 16666, Tehran, Iran.
Mohammadreza RazzaghiNegah Eye Hospital, Tehran, Iran.
Alireza RamezaniDepartment of Ophthalmology and Ophthalmic Research Center, Labbafinejad Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St., 16666, Tehran, Iran.
Mohsen AzarminaDepartment of Ophthalmology and Ophthalmic Research Center, Labbafinejad Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St., 16666, Tehran, Iran.
Mehdi YaseriDepartment of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.
Roham SoheilianDepartment of Ophthalmology and Ophthalmic Research Center, Labbafinejad Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St., 16666, Tehran, Iran.
Masoud SoheilianDepartment of Ophthalmology and Ophthalmic Research Center, Labbafinejad Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St., 16666, Tehran, Iran. masoud_soheilian@yahoo.com.
Shahid Beheshti University of Medical Sciences · IRAhvaz Jundishapur University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to evaluate the structural and functional effects of systemic oxygen therapy and enalapril in patients with diabetic macular ischemia (DMI). This randomized clinical trial consisted of 105 eyes with DMI divided into three groups. Group I received systemic oxygen by face mask at a flow rate of 10 L/min; Group II received 5 mg enalapril daily; and Group III received placebo tablets for 3 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography (OCT), extent of foveal avascular zone (FAZ) on fluorescein angiograms, and electroretinograms (ERG) were obtained at baseline and after 3 and 6 months. Overall, 102 patients completed the study. Baseline characteristics were not significantly different among groups. Significant improvement in BCVA and decrease in CMT and FAZ occurred at months 3 and 6 in oxygen group compared to deterioration in enalapril and control groups (All P values <0.001). ERG parameters were significantly better in oxygen group compared to enalapril group at months 3 and 6 and better than those in control group at month 3. Normobaric oxygen therapy for 3 months in DMI decreased CMT and FAZ and improved BCVA and ERG parameters. Enalapril did not show any favorable effect.

Indexed as

AdultAgedAngiotensin-Converting Enzyme InhibitorsDiabetic RetinopathyEnalaprilFemaleHumansIschemiaMacula LuteaMacular EdemaMaleMiddle AgedOxygenRetinal DiseasesTomography, Optical CoherenceVisual AcuityAngiotensin-Converting Enzyme InhibitorsEnalaprilOxygenDiabetic macular ischemiaEnalaprilIschemic maculopathyOxygen therapy

Identifiers

PMID26292645
OpenAlexW1201319859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.